Author name: Yali Friedman

Biotech Startups: Take Your Time Until startups’ products are close to gaining approval, there’s no reason why smart investors would […]

Has the debate on GM crops been misleading? More than a hundred scientists have written to Tony Blair, complaining about

Are Adult Stem Cells a Bust? Opponents of research on embryonic stem cells have insisted that adult stem cells are

Is the US pharmaceuticals industry losing its way? The EU generally looks to the US as its model for pharmaceuticals

U.S. drug companies curb supplies to Canadian exporters As the political fight over drug imports into the United States intensifies,

The next big thing is… According to the most recent MoneyTree Survey, a report put together by PricewaterhouseCoopers, Thomson Venture

Pharmaceutical Makers Turn To CRM After years of blockbuster medications that literally change the way their customers live, drugmakers are

Fog Begins to Lift with Q3 Biotech Numbers Certain market indicators for 2003�s third quarter suggest that at least some

India emerges as new drug trial hot spot Biotech entrepreneurs see Indian clinical trials � which can cut costs by

Who’s Going To Pay For Global Health? The amazingly swift global response to the SARS outbreak earlier this year demonstrated